<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076997</url>
  </required_header>
  <id_info>
    <org_study_id>H-33119</org_study_id>
    <nct_id>NCT02076997</nct_id>
  </id_info>
  <brief_title>Individualized High Dose Methotrexate to Treat Cancer in Children Who Have a Significant Risk for Side Effects to Methotrexate</brief_title>
  <official_title>Individualized High Dose Methotrexate for the Treatment of Malignancies in Children and Adolescents With a Significant Risk for Methotrexate Toxicities</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Texas Children's Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pediatric cancer patients are being asked to take part in this study who have a cancer that&#xD;
      is treated with high doses of the drug methotrexate (MTX). In addition, these patients have&#xD;
      either had significant side effects to methotrexate in the past or their doctor thinks that&#xD;
      they are at high risk for side effects from receiving methotrexate. Methotrexate is a&#xD;
      cancer-fighting drug that is very important in the treatment of leukemia.&#xD;
&#xD;
      In this study, investigators are testing a new method of giving high dose methotrexate to&#xD;
      cancer patients which may reduce the chances that the level of methotrexate in the blood is&#xD;
      too high. When the levels are too high this is thought to lead to an increase in side&#xD;
      effects. Side effects are unintended and unwanted results of treatment.&#xD;
&#xD;
      The initial ordered amount of methotrexate and the period over which methotrexate is given&#xD;
      will not change from the current standard of care (meaning what is usually done by doctors,&#xD;
      and would likely be done if the patient was not on this study). This study is testing a new&#xD;
      method of monitoring and potentially adjusting the final amount of methotrexate that the&#xD;
      patient will end up receiving based on levels of methotrexate in the blood in the first 24&#xD;
      hours in order to try to prevent side effects in patients with a previous history of side&#xD;
      effects from methotrexate or who are at high risk for having side effects.&#xD;
&#xD;
      On this study the investigators will check methotrexate levels in the blood 2 hours after the&#xD;
      patient starts receiving the drug and the investigators will lower the dose of methotrexate&#xD;
      if needed. Investigators will do the same thing again 6-8 hours later.&#xD;
&#xD;
      Investigators will also collect an optional blood sample from the patient because the&#xD;
      investigators want to study how genetic (DNA) differences are involved in how the body&#xD;
      processes methotrexate.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study participant will receive the drug methotrexate as a patient in the hospital. High&#xD;
      dose methotrexate will be given as a 24-hour infusion as part of the care determined to be&#xD;
      necessary by their doctor. Infusion means the drug is given using a needle or tubing inserted&#xD;
      into a vein (also called IV).&#xD;
&#xD;
      The standard of care in patients receiving high dose methotrexate is to give the entire dose&#xD;
      of methotrexate, without adjustment, and to then check the concentration of methotrexate in&#xD;
      the blood at the end of the infusion. Most patients will have a level of methotrexate in&#xD;
      their blood which is good to treat cancer and keep side effects at a minimum. However, other&#xD;
      patients have a level of methotrexate at the end of the 24-hour infusion which is very high&#xD;
      and is thought to lead to an increase in side effects.&#xD;
&#xD;
      In this study, investigators are testing a method of giving methotrexate which may reduce the&#xD;
      chances that the level of methotrexate in the blood at the end of the infusion is too high.&#xD;
      This will be done by checking the methotrexate level in the blood at two times during the&#xD;
      24-hour infusion and reducing the dose of methotrexate being given if the levels are not&#xD;
      thought to be in the correct range (the level is too high). Reducing the dose may result in&#xD;
      the patient receiving a lower total dose of methotrexate than initially ordered. However, it&#xD;
      may also result in a more preferred concentration of methotrexate in the blood at the end of&#xD;
      the infusion.&#xD;
&#xD;
      It is possible that in the past the patient's doctor may have chosen to reduce the amount of&#xD;
      methotrexate given because the patient had side effects. In this study, all patients will&#xD;
      start out receiving the standard dose of methotrexate. Therefore, by participating in this&#xD;
      study, the amount of methotrexate ordered at the start of the infusion may be higher than&#xD;
      what the patient received previously.&#xD;
&#xD;
      Before and after the patient receives high dose methotrexate, the patient will receive IV&#xD;
      fluids. In order to minimize side effects, methotrexate levels will also be closely monitored&#xD;
      after the infusion and the patient will receive supportive medicines as needed. The patient&#xD;
      will receive the drug Leucovorin (administered by mouth every 6 hours for minimum of 3&#xD;
      doses). The monitoring and supportive care that the patient will receive at the end of the&#xD;
      methotrexate infusion, the amount of IV fluids, and the dose or duration of Leucovorin&#xD;
      received will be done based on standard guidelines and are not part of this study.&#xD;
&#xD;
      After receiving the 24-hour high dose methotrexate, this individualized monitoring plan will&#xD;
      end and management of the patient's methotrexate levels will continue according to standard&#xD;
      guidelines.&#xD;
&#xD;
      High dose methotrexate may be given to the patient multiple times at the discretion of their&#xD;
      doctor. While on this study, the patient will receive methotrexate using the methods of this&#xD;
      study (however, they will only have blood drawn one time for optional DNA testing). The&#xD;
      patient, his/her parent, or the doctor may decide to withdraw the patient from this study at&#xD;
      any time if they do not think that it is in the patient's best interest to continue to&#xD;
      receive methotrexate in the manner being investigated in this study.&#xD;
&#xD;
      STUDY RELATED TESTS AND PROCEDURES&#xD;
&#xD;
      At study entry, the following will occur:&#xD;
&#xD;
        -  The patient will have a physical exam&#xD;
&#xD;
        -  Collection of blood samples for routine blood tests and research blood tests.&#xD;
           Approximately 1-2 teaspoons of blood will be taken for research blood tests.&#xD;
&#xD;
        -  Review of the patient's medical and medication history to collect information.&#xD;
&#xD;
      During treatment and after treatment the following will occur:&#xD;
&#xD;
        -  Collection of blood samples for routine blood tests and research blood tests.&#xD;
           Approximately ½ teaspoon of blood will be taken at times 2, 6 (or 8), 24, 36, 42, and 48&#xD;
           hours. The blood collected at 2 and 6 (or 8) and 24 hours is for the research blood&#xD;
           tests.&#xD;
&#xD;
        -  Review of the patient's medical and medication history to collect information.&#xD;
&#xD;
      The research blood tests are done to see how much methotrexate is in the body, how the body&#xD;
      handles the drug, and to do DNA studies. The DNA will be tested to look for small changes&#xD;
      called Single Nucleotide Polymorphisms (SNP). These small changes sometimes explain why&#xD;
      different people have different reactions to drugs. The total amount of blood drawn for the&#xD;
      research studies is approximately 3 teaspoons.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2014</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 30, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Success (Achieving an End Infusion Peripheral Blood Methotrexate Concentration Between 50-80 μM)</measure>
    <time_frame>1 month</time_frame>
    <description>1a) Calculate the incidence of success with the new protocol (achieving an end infusion peripheral blood methotrexate concentration between 50-80 μM)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of &gt;Grade 3 Nephrotoxicity</measure>
    <time_frame>2.5 months</time_frame>
    <description>Calculate the incidence of &gt;grade 3 nephrotoxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Neurotoxicity</measure>
    <time_frame>2.5 months</time_frame>
    <description>Calculate the incidence of neurotoxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Mucositis</measure>
    <time_frame>2.5 months</time_frame>
    <description>Calculate the incidence of mucositis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Hepatoxicity</measure>
    <time_frame>2.5 months</time_frame>
    <description>Calculate the incidence of hepatotoxicity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Myelosuppression</measure>
    <time_frame>2.5 months</time_frame>
    <description>grade &gt;/= 3 hematological toxicity</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Description of the Genotype of Various Methotrexate Metabolizing SNPs</measure>
    <time_frame>4 weeks</time_frame>
    <description>We described the genotype of various identified methotrexate metabolizing SNPs</description>
  </other_outcome>
  <other_outcome>
    <measure>Examination of Predictors of Success in Achieving Goal Concentration of Methotrexate</measure>
    <time_frame>4 weeks</time_frame>
    <description>We examined the predictors of success in achieving goal concentration of methotrexate</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Cancer</condition>
  <arm_group>
    <arm_group_label>Individualized High Dose Methotrexate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Individualized high dose methotrexate given as a 24-hour infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
    <arm_group_label>Individualized High Dose Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age: Patients must be greater than or equal to 365 days and less than 23 years of age&#xD;
             at the time of enrollment.&#xD;
&#xD;
          2. Diagnosis: Patients with any malignancy who will receive high dose methotrexate&#xD;
             (HDMTX) given as a 5 g/m2 infusion over 24 hours and a history of ≥ 1 of the&#xD;
             following:&#xD;
&#xD;
               -  Documented decreased renal function, defined as Creatinine greater than 1.5 x&#xD;
                  baseline or glomerular filtration rate (GFR) &lt;65ml/min/1.73m2.&#xD;
&#xD;
               -  History of prior nephrotoxicity with HDMTX as evidence by increased creatinine to&#xD;
                  1.5 x baseline or need for dialysis or carboxypeptidase&#xD;
&#xD;
               -  History of Grade 3 adverse event (AE) related to HDMTX (mucositis,&#xD;
                  myelosuppression, nephrotoxicity, hepatotoxicity) based on the NIH Common&#xD;
                  Terminology Criteria for Adverse Events (CTCAE) version 4.0&#xD;
&#xD;
               -  Provider concern patient is at risk for MTX toxicity, such as a prior history of&#xD;
                  treatment with nephrotoxic chemotherapy, history of HDMTX-related neurotoxicity,&#xD;
                  or antimicrobial/antifungal therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Unable to draw labs for HDMTX serum concentration&#xD;
&#xD;
          2. Enrollment on a protocol (COG or other) which restricts proposed dose modifications&#xD;
&#xD;
          3. Patients with Trisomy 21&#xD;
&#xD;
          4. Patients with greater than grade 1 neurologic toxicity at the time of enrollment that&#xD;
             is attributed to unresolved prior methotrexate toxicity&#xD;
&#xD;
          5. Patients with greater than or equal to grade 3 chronic kidney disease at enrollment&#xD;
             (eGFR or creatine clearance (CrCl) less than 30ml/min/1.73m2)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>22 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer H Foster, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Children's Hospital</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 28, 2014</study_first_submitted>
  <study_first_submitted_qc>February 28, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 4, 2014</study_first_posted>
  <results_first_submitted>January 16, 2020</results_first_submitted>
  <results_first_submitted_qc>February 8, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 24, 2021</results_first_posted>
  <last_update_submitted>February 8, 2021</last_update_submitted>
  <last_update_submitted_qc>February 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Jennifer Foster</investigator_full_name>
    <investigator_title>Assistant Professor of Pediatrics</investigator_title>
  </responsible_party>
  <keyword>Cancer</keyword>
  <keyword>High Dose Methotrexate</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 17, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/97/NCT02076997/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Individualized High Dose Methotrexate</title>
          <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Individualized High Dose Methotrexate</title>
          <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13" lower_limit="1" upper_limit="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Success (Achieving an End Infusion Peripheral Blood Methotrexate Concentration Between 50-80 μM)</title>
        <description>1a) Calculate the incidence of success with the new protocol (achieving an end infusion peripheral blood methotrexate concentration between 50-80 μM)</description>
        <time_frame>1 month</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Success (Achieving an End Infusion Peripheral Blood Methotrexate Concentration Between 50-80 μM)</title>
          <description>1a) Calculate the incidence of success with the new protocol (achieving an end infusion peripheral blood methotrexate concentration between 50-80 μM)</description>
          <units>uM</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57" spread="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>&lt;0.01</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of &gt;Grade 3 Nephrotoxicity</title>
        <description>Calculate the incidence of &gt;grade 3 nephrotoxicity</description>
        <time_frame>2.5 months</time_frame>
        <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of &gt;Grade 3 Nephrotoxicity</title>
          <description>Calculate the incidence of &gt;grade 3 nephrotoxicity</description>
          <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Neurotoxicity</title>
        <description>Calculate the incidence of neurotoxicity</description>
        <time_frame>2.5 months</time_frame>
        <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Neurotoxicity</title>
          <description>Calculate the incidence of neurotoxicity</description>
          <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Mucositis</title>
        <description>Calculate the incidence of mucositis</description>
        <time_frame>2.5 months</time_frame>
        <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Mucositis</title>
          <description>Calculate the incidence of mucositis</description>
          <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Hepatoxicity</title>
        <description>Calculate the incidence of hepatotoxicity</description>
        <time_frame>2.5 months</time_frame>
        <population>total infusions</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Hepatoxicity</title>
          <description>Calculate the incidence of hepatotoxicity</description>
          <population>total infusions</population>
          <units>infusions</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Myelosuppression</title>
        <description>grade &gt;/= 3 hematological toxicity</description>
        <time_frame>2.5 months</time_frame>
        <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Myelosuppression</title>
          <description>grade &gt;/= 3 hematological toxicity</description>
          <population>22 patients were enrolled for a total of 54 cycles of methotrexate. Toxicities were recorded by cycle</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="54"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Description of the Genotype of Various Methotrexate Metabolizing SNPs</title>
        <description>We described the genotype of various identified methotrexate metabolizing SNPs</description>
        <time_frame>4 weeks</time_frame>
        <population>The SNP analysis was descriptive data</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Description of the Genotype of Various Methotrexate Metabolizing SNPs</title>
          <description>We described the genotype of various identified methotrexate metabolizing SNPs</description>
          <population>The SNP analysis was descriptive data</population>
          <units>percent SNPs in the population</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="22"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>rs1801394</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs1801133</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs1801131</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs7317112</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>rs4149056</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>There was no statistical analysis performed for this aim as it was descriptive</groups_desc>
            <non_inferiority_type>Other</non_inferiority_type>
            <other_analysis_desc>There was no statistical analysis performed for this aim as it was descriptive</other_analysis_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Examination of Predictors of Success in Achieving Goal Concentration of Methotrexate</title>
        <description>We examined the predictors of success in achieving goal concentration of methotrexate</description>
        <time_frame>4 weeks</time_frame>
        <population>Among subjects who required at least one dose adjustment on study (n = 14), those who carried one or two copies of the minor allele of the C677T methylenetetrahydrofolate reductase (MTHFR) gene had an OR 6.7 (95% CI 0.49-91.3) of achieving success as defined by the protocol</population>
        <group_list>
          <group group_id="O1">
            <title>Individualized High Dose Methotrexate</title>
            <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
          </group>
        </group_list>
        <measure>
          <title>Examination of Predictors of Success in Achieving Goal Concentration of Methotrexate</title>
          <description>We examined the predictors of success in achieving goal concentration of methotrexate</description>
          <population>Among subjects who required at least one dose adjustment on study (n = 14), those who carried one or two copies of the minor allele of the C677T methylenetetrahydrofolate reductase (MTHFR) gene had an OR 6.7 (95% CI 0.49-91.3) of achieving success as defined by the protocol</population>
          <units>Odds Ratio</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="0.49" upper_limit="91.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>6.7</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Patients were followed for 4 weeks following last HDMTX or until next chemotherapy, whichever came sooner</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Individualized High Dose Methotrexate</title>
          <description>Individualized high dose methotrexate given as a 24-hour infusion.&#xD;
Methotrexate: Patients will receive 5g/m^2 high dose methotrexate as a 24 hour infusion.&#xD;
The methotrexate level in the blood will be checked at two times during the 24-infusion. The dose will be reduced based on the level in the blood.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="22"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Jennifer Foster</name_or_title>
      <organization>Baylor College of Medicine</organization>
      <phone>832-824-4646</phone>
      <email>jhfoster@texaschildrens.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

